Jianmin Fang
Tongji University(CN)Biocure (United States)(US)Xi'an Jiaotong University(CN)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations
Most-Cited Works
- → The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors(2024)134 cited
- → A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer(2023)42 cited
- → A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.(2019)39 cited
- → A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis(2024)36 cited
- → RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.(2022)33 cited
- → Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.(2018)32 cited
- → Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma(2023)17 cited
- → ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma(2023)15 cited
- → The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.(2024)11 cited
- → Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.(2024)7 cited